TY - JOUR
T1 - Progression of Hodgkin lymphoma and plasma cell neoplasms Report from the 2021 SH/EAHP workshop
AU - Nejati, Reza
AU - Amador, Catalina
AU - Czader, Magdalena
AU - Thacker, Elizabeth
AU - Thakkar, Devang
AU - Dave, Sandeep S.
AU - Dogan, Ahmet
AU - Duffield, Amy
AU - Goodlad, John R.
AU - Ott, German
AU - Wasik, Mariusz A.
AU - Xiao, Wenbin
AU - Cook, James R.
N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2023/6/1
Y1 - 2023/6/1
N2 - Objectives: To summarize cases submitted to the 2021 Society for Hematopathology/ European Association for Haematopathology Workshop under the categories of progression of Hodgkin lymphoma, plasmablastic myeloma, and plasma cell myeloma. Methods: The workshop panel reviewed 20 cases covered in this session. In addition, whole-exome sequencing (WES) and whole-genome RNA expression analysis were performed on 10 submitted cases, including 6 Hodgkin lymphoma and 4 plasma neoplasm cases. Results: The cases of Hodgkin lymphoma included transformed cases to or from various types of B-cell lymphoma with 1 exception, which had T-cell differentiation. The cases of plasma cell neoplasms included cases with plasmablastic progression, progression to plasma cell leukemia, and secondary B-lymphoblastic leukemia. Gene variants identified by WES included some known to be recurrent in Hodgkin lymphoma and plasma cell neoplasm. All submitted Hodgkin lymphoma samples showed 1 or more of these mutations: SOCS1, FGFR2, KMT2D, RIT1, SPEN, STAT6, TET2, TNFAIP3, and ZNF217. Conclusions: Better molecular characterization of both of these neoplasms and mechanisms of progression will help us to better understand mechanisms of progression and perhaps develop better prognostic models, as well as identifying novel therapeutic targets.
AB - Objectives: To summarize cases submitted to the 2021 Society for Hematopathology/ European Association for Haematopathology Workshop under the categories of progression of Hodgkin lymphoma, plasmablastic myeloma, and plasma cell myeloma. Methods: The workshop panel reviewed 20 cases covered in this session. In addition, whole-exome sequencing (WES) and whole-genome RNA expression analysis were performed on 10 submitted cases, including 6 Hodgkin lymphoma and 4 plasma neoplasm cases. Results: The cases of Hodgkin lymphoma included transformed cases to or from various types of B-cell lymphoma with 1 exception, which had T-cell differentiation. The cases of plasma cell neoplasms included cases with plasmablastic progression, progression to plasma cell leukemia, and secondary B-lymphoblastic leukemia. Gene variants identified by WES included some known to be recurrent in Hodgkin lymphoma and plasma cell neoplasm. All submitted Hodgkin lymphoma samples showed 1 or more of these mutations: SOCS1, FGFR2, KMT2D, RIT1, SPEN, STAT6, TET2, TNFAIP3, and ZNF217. Conclusions: Better molecular characterization of both of these neoplasms and mechanisms of progression will help us to better understand mechanisms of progression and perhaps develop better prognostic models, as well as identifying novel therapeutic targets.
KW - Hodgkin lymphoma
KW - Plasma cell leukemia
KW - Plasma cell neoplasm
KW - Progression
KW - Transformation
UR - http://www.scopus.com/inward/record.url?scp=85160966651&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000973240900001&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1093/ajcp/aqad023
DO - 10.1093/ajcp/aqad023
M3 - Review article
C2 - 37085150
SN - 0002-9173
VL - 159
SP - 598
EP - 613
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 6
ER -